Background:

Atopic dermatitis (AD) significantly affects patients’ quality of life.

Objectives:

To assess long-term disease control in AD patients receiving dupilumab (DUP) treatment and the applicability and relevance of the Atopic Dermatitis Control Tool (ADCT) in this context.

Methods:

A retrospective observational study of patients with AD followed in an immunoalergology outpatient clinic in 2 Hospital Centers, who completed at least 6 months of DUP. Disease control was assessed using the ADCT in a single moment. Correlations between ADCT and AD duration, severity assessment scores SCORAD, EASI, DLQI, numerical scales (NRS) of pruritus and sleep, total IgE and eosinophilia were evaluated. We analyzed the evolution of these scores and biomarkers over the course of treatment in relation to baseline (T0) and the diferences between well and poorly controlled patients for these variables.

Results:

29 patients were included, 51.7% female, mean age of 35,6 years, median AD duration of 29 years and mean duration of DUP of 14 months. According to ADCT, 12 patients(41%) reported poor AD control. Globally, there was a significant reduction in EASI, SCORAD, NRS-pruritis, NRS-sleep, and DLQI from T0 to the time of ADCT assessment. Patients well-controlled according to ADCT had a significant reduction in the median score of SCORAD, EASI, and DLQI irrespective of the duration of treatment. Median total IgE significantly decreased at 6 and 12 months of DUP. Patients with poor AD control according to the ADCT had lower baseline total IgE values and patients with higher baseline total IgE had a greater improvement in DLQI under DUP.

Conclusions:

In this study, 41% of patients reported poor AD control according to the ADCT. There was a positive correlation between ADCT and SCORAD and DLQI evaluated at the same time point. Lower baseline total IgE values were associated with poor AD control according to ADCT.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )